Discontinue use at least 1 wk prior to treatment in patients treated w/ oral phosphate & active vit D analogues; if serious hypersensitivity reactions occur. Interrupt administration if patient experiences severe inj site reactions. Monitor for signs & symptoms of nephrocalcinosis, by renal ultrasonography at start of treatment & every 6 mth for 1st 12 mth of treatment, & annually thereafter. Monitor plasma alkaline phosphatase, Ca, parathyroid hormone & creatinine every 6 mth (every 3 mth for childn 1-2 yr); urine Ca & phosphate every 3 mth; levels of fasting serum phosphate. Periodic measurement of post-prandial serum phosphate & parathyroid hormone. May affect ability to drive & use machines. Not to be given in patients w/ severe renal disease or ESRD. Not recommended in women of childbearing potential not using contraception & during pregnancy. Lactation. Childn <1 yr. Elderly >65 yr.
Sign Out
